Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Hodgkin Disease 20Lymphoma 6Urinary Bladder Neoplasms 3Urothelial Carcinoma of the Bladder 1Rhabdoid Tumor 1Renal Pelvis and Ureter Urothelial Carcinoma 1Neoplasms 1Muscle Invasive Bladder Urothelial Carcinoma 1Lymphoma, Large-Cell, Anaplastic 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Choroid Plexus Neoplasms 1Childhood Solid Tumor 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Astrocytoma 1

Interventions

pembrolizumab 44Gemcitabine 23enfortumab vedotin 21Nivolumab 20Cisplatin 17avelumab 16Magnetic Resonance Spectroscopy 15Carboplatin 14atezolizumab 13Specimen Handling 12Docetaxel 11sacituzumab govitecan 9Paclitaxel 8Ipilimumab 8durvalumab 6Mitomycin 5Fluorodeoxyglucose F18 5cabozantinib 4Taxes 4toripalimab 3pemigatinib 3erdafitinib 3X-Rays 3Radiosurgery 3Platinum 3Pemetrexed 3Immunoglobulin G 3CTLA-4 Antigen 3Biopsy 3ALT-803 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Vinblastine × 1 year × Clear all
NCT05137262 2026-02-18

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
12 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡